Hematologic Oncology Update

Featuring perspectives from Dr Hans Lee and Dr Noopur Raje, including the following topics:Introduction (0:00)Integrating Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies into the Management of Relapsed/Refractory Multiple Myeloma (R/R MM) — Dr Raje (4:30)Antibody-Drug Conjugates and Other Emerging Therapies for R/R MM — Dr Lee (28:33)CME information and select publications

Featuring perspectives from Dr John N Allan and Dr Adam Kittai, including the following topics:Introduction (0:00)Current Management of Newly Diagnosed Chronic Lymphocytic Leukemia — Dr Allan (8:47)Noncovalent Bruton Tyrosine Kinase Inhibitors and Other Novel Strategies — Dr Kittai (38:14)CME information and select publications

Featuring perspectives from Dr Manali Kamdar, Dr Krish Patel and Dr Gilles Salles, including the following topics:Introduction (0:00)Antibody-Drug Conjugates and Other Novel Strategies for the Management of Diffuse Large B-Cell Lymphoma (DLBCL) — Prof Salles (7:05)Current and Future Role of Monoclonal and Bispecific Antibodies in the Management of DLBCL — Dr Patel (26:21)Chimeric Antigen Receptor (CAR) T-Cell Therapy for DLBCL — Dr Kamdar (43:12)CAR T-Cell Therapy for Follicular Lymphoma (FL) — Prof Salles (1:08:33)Other Approved and Emerging Novel Therapies for FL — Dr Patel (1:24:44)Integrating Bispecific Antibodies into the Management of FL — Dr Kamdar (1:41:34)CME information and select publications

Dr Jennifer R Brown and Prof Wojciech Jurczak discuss the selection and sequencing of Bruton tyrosine kinase-targeted therapy for patients with chronic lymphocytic leukemia and summarize major advances in the treatment landscape over the past year.CME information and select publications here.

Dr Paul G Richardson from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses how CELMoDs function, available data with these agents and their possible future role in the treatment of multiple myeloma.CME information and select publications here.

Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.CME information and select publications here.

Dr Paul G Richardson from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses how CELMoDs function, available data with these agents and their possible future role in the treatment of multiple myeloma.CME information and select publications here.

Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.CME information and select publications here.

Dr Bijal Shah from Moffitt Cancer Center in Tampa, Florida, discusses the role of BiTEs in the management of ALL.CME information and select publications here.

Prof Constantine Tam from Monash University in Melbourne, Australia, reviews recent datasets and discusses their implications for current and future management of chronic lymphocytic leukemia.CME information and select publications here.

Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.CME information and select publications here.

Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.CME information and select publications here.

Dr Natalie S Callander from the University of Wisconsin Carbone Cancer Center in Madison and Dr Paul G Richardson from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss the potential role of CELMoDs in the management of multiple myeloma, supporting clinical data and ongoing investigations.CME information and select publications here.

Dr Sagar Lonial from Winship Cancer Institute in Atlanta, Georgia, discusses recent clinical developments with BCMA-targeted therapy and investigational agents for relapsed/refractory multiple myeloma presented at ASH 2025.CME information and select publications here.

Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston, Dr Cindy Neunert from Columbia University Irving Medical Center in New York and Prof Francesco Zaja from ASUGI in Trieste, Italy discuss cases of immune thrombocytopenia and recent findings from the 2025 ASH Annual Meeting.CME information and select publications here.

Dr Sagar Lonial from Winship Cancer Institute in Atlanta, Georgia, discusses recent clinical developments with BCMA-targeted therapy and investigational agents for relapsed/refractory multiple myeloma presented at ASH 2025.CME information and select publications here.

Prof Michael Dickinson from Peter MacCallum Cancer Centre in Melbourne, Australia, and Dr Laurie H Sehn from the University of British Columbia in Vancouver, Canada, discuss clinical cases and recent findings from the 2025 ASH Annual Meeting relating to the use of bispecific antibodies in the management of lymphoma.CME information and select publications here.

Dr Sagar Lonial from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr María-Victoria Mateos from the University Hospital of Salamanca in Salamanca, Spain, discuss cases of relapsed/refractory multiple myeloma and recentresearch findings from the 2025 ASH Annual Meeting. CME information and select publications here.

Dr Nancy L Bartlett from the Washington University School of Medicine, Dr John P Leonard from the Perlmutter Cancer Center, Dr Matthew Matasar from Rutgers Cancer Institute, Dr Loretta J Nastoupil from Southwest Oncology and Prof Pier Luigi Zinzani from the University of Bologna in Italy discuss recent updates on available and novel treatment strategies for follicular lymphoma and diffuse large B-cell lymphoma. CME information and select publications here.

Prof Claire Harrison from Guy’s and St Thomas’ NHS Foundation Trust in London, Dr Andrew T Kuykendall from Moffitt Cancer Center, Dr Stephen T Oh from the Washington University School of Medicine, Dr Jeanne Palmer from the Mayo Clinic School of Medicine and Dr Raajit K Rampal from Memorial Sloan Kettering Cancer Center discuss recent updates on available and novel treatment strategies for myelofibrosis and systemic mastocytosis.CME information and select publications here.

Dr Matthew S Davids from Dana-Farber Cancer Institute, Dr Bita Fakhri from Stanford University School of Medicine, Prof Constantine Tam from Alfred Health in Melbourne, Australia, and Dr Jennifer Woyach from The Ohio State University Comprehensive Cancer Center review the treatment landscape for patients with chronic lymphocytic leukemia and discuss current research immediately before the 67th ASH Annual Meeting.CME information and select publications here.

Dr Harry Paul Erba from the Duke Cancer Institute, Dr Amir Fathi from Massachusetts General Hospital, Dr Tara L Lin from The University of Kansas Medical Center, Dr Alexander Perl from the University of Pennsylvania’s Abramson Cancer Center and Dr Eytan M Stein from Memorial Sloan Kettering Cancer Center discuss recent data surrounding the management of AML and their perspectives on clinical application.CME information and select publications here.

Dr Kerry A Rogers from The Ohio State University in Columbus summarizes the treatment landscape and reviews relevant clinical datasets for patients with chronic lymphocytic leukemia. CME information and select publications here.

Dr Jeremy S Abramson from Massachusetts General Hospital in Boston and Dr Loretta J Nastoupil from CommonSpirit Mercy Hospital in Durango, Colorado, discuss the clinical applications of chimeric antigen receptor T-cell therapy for patients with non-Hodgkin lymphoma.   CME information and select publications here.

Dr Matthew Lunning from the Fred and Pamela Buffett Cancer Center in Omaha, Nebraska, discusses recent updates on the management of toxicities associated with CAR T-cell therapy.   CME information and select publications here.

Dr Jeremy S Abramson from Massachusetts General Hospital in Boston and Dr Manali Kamdar from the University of Colorado Cancer Center in Aurora discuss patient questions and experiences with CAR T-cell therapy for non-Hodgkin lymphoma. Educational information and select publications here.

Dr Matthew Lunning and Dr Sonali M Smith share their perspectives on the evolving therapeutic landscape for patients with diffuse large B-cell lymphoma and follicular lymphoma. CME information and select publications here.

Dr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, discusses recent datasets and their implications for the current and future management of acute myeloid leukemia.  CME information and select publications here.

Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, and Dr Brad S Kahl from Siteman Cancer Center in St Louis, Missouri, review recent datasets and their significance for the management of various forms of non-Hodgkin lymphoma. CME information and select publications here.

Dr Jeremy S Abramson from Massachusetts General Hospital in Boston, Dr Jennifer Crombie from Dana-Farber Cancer Institute also in Boston and Dr Laurie H Sehn from the BC Cancer Centre for Lymphoid Cancer in Vancouver, British Columbia, Canada, discuss recent updates on available and novel treatment strategies for follicular lymphoma.  CE information and select publications here.

Dr Ghayas Issa from The University of Texas MD Anderson Cancer Center in Houston discusses data guiding the use of menin inhibitors for patients with acute myeloid leukemia and select alterations. CME information and select publications here.

Prof Meletios-Athanasios (Thanos) C Dimopoulos from Alexandra Hospital in Athens, Greece, Dr Hans Lee from Sarah Cannon Research Institute in Nashville, Tennessee, Dr Joseph Mikhael from City of Hope Cancer Center in Phoenix, Arizona, and Dr Noopur Raje from Massachusetts General Hospital in Boston discuss recent updates on available and novel treatment strategies for relapsed/refractory multiple myeloma.  CE information and select publications here.

Dr Beth Faiman from Case Comprehensive Cancer Center in Cleveland, Ohio, discusses nursing considerations with CAR T-cell therapy for patients with multiple myeloma. NCPD information and select publications here.

Dr Neel Pasricha from the University of California, San Franciso, reviews corneal and other ophthalmic toxicities associated with antibody-drug conjugates and other cancer therapies and strategies for their prevention and management.   CME information and select publications here.

Prof Rebecca A Dent from National Cancer Centre Singapore, Dr Hans Lee from Sara Cannon Research Institute in Nashville, Tennessee, Dr Neel Pasricha from the University of California, San Francisco, and Dr Tiffany A Richards from The University of Texas MD Anderson Cancer Center in Houston, discuss strategies to manage ocular toxicities associated with antibody-drug conjugates and other cancer therapies. CME information and select publications here.

Ms Charise Gleason from Emory Healthcare in Atlanta, Georgia, discusses the evolution of first-line therapy for patients with multiple myeloma. NCPD information and select publications here.

Prof Xavier Leleu from Poitiers University Hospital in Poitiers, France, discusses nursing considerations in the treatment of newly diagnosed multiple myeloma. NCPD information and select publications here.

Dr Natalie S Callander and Dr Sagar Lonial provide clinical perspectives on the treatment and disease-management course for patients with relapsed/refractory multiple myeloma. CME information and select publications here.

For this patient-focused webinar, medical oncologist Dr Neil Love is joined by Dr Natalie S Callander from the University of Wisconsin Carbone Cancer Center in Madison and Dr Sagar Lonial from the Winship Cancer Institute of Emory University in Atlanta, Georgia, to discuss the patient experience associated with the diagnosis and treatment of relapsed/refractory multiple myeloma. Educational and faculty information here.

Dr Jorge Cortes from Georgia Cancer Center at Augusta University discusses patient cases and summarizes current treatment approaches for FLT3- and IDH1/2-mutant acute myeloid leukemia. CME information and select publications here.

Prof Xavier Leleu and Dr Peter Voorhees review relevant clinical data regarding first-line treatment decisions for patients with multiple myeloma. CME information and select publications here.

Dr Catherine Coombs and Dr William Wierda summarize major treatment advances in chronic lymphocytic leukemia presented at the 2025 American Society of Clinical Oncology Annual Meeting and review ongoing clinical trials. CME information and select publications here.

Dr Ajay K Nooka from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr Paul G Richardson from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss recent updates on available and novel treatment strategies for multiple myeloma. CME information and select publications here.

Dr Bita Fakhri, Dr Jeff Sharman, and nurse practitioners Dr Jacqueline Broadway-Duren and Ms Corinne Hoffman discuss the current treatment landscape for chronic lymphocytic leukemia and strategies to mitigate and manage treatment-emergent adverse events.   NCPD information and select publications here.

Dr Jeremy Abramson from Massachusetts General Hospital in Boston, Dr Joshua Brody from the Tisch Cancer Institute in New York, New York, Dr Christopher Flowers from The University of Texas MD Anderson Cancer Center in Houston, Dr Ann LaCasce from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Tycel Phillips from City of Hope Comprehensive Cancer Center in Duarte, California, discuss patient cases and provide their perspectives on clinical datasets informing the care of patients with non-Hodgkin lymphoma. CME information and select publications here.

Dr Christopher Flowers and Dr Manali Kamdar summarize the clinical treatment landscape for patients with non-Hodgkin lymphoma, supported by clinical perspectives and management strategies from nurse practitioners Ms Robin Klebig and Ms Caitlin Murphy. NCPD information and select publications here.

Dr Michael Mauro, Dr Neil Shah, and nurse practitioners Ms Ilene Galinsky and Dr Sara Tinsley-Vance discuss important nursing considerations in the modern treatment of chronic myeloid leukemia. NCPD information and select publications here.

Dr Patrick Wen from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses the current and future management of IDH-mutant gliomas.  CME information and select publications here.

Prof Meletios-Athanasios (Thanos) C Dimopoulos from the National and Kapodistrian University of Athens and Alexandra Hospital in Athens, Greece, and Dr Robert Z Orlowski from The University of Texas MD Anderson Cancer Center in Houston, Texas, provide their perspectives on relevant new clinical data in multiple myeloma and their application to disease treatment. CME information and select publications here.

Professor Claire Harrison from the Guy’s and St Thomas’ NHS Foundation Trust in London, United Kingdom, and Dr John Mascarenas from The Tisch Cancer Institute in New York, New York, provide their perspectives on relevant new clinical data in myelofibrosis and discuss their application to treatment. CME information and select publications here.